Background And Objectives: Impaired renal function in atherosclerotic renovascular disease (ARD) may be the result of crosstalk between atherosclerotic renovascular stenosis and amplified oxidative stress, inflammation and fibrosis. Berberine (BBR) regulates cholesterol metabolism and exerts antioxidant effects. Accordingly, we hypothesized that BBR treatment may ameliorate ARD-induced kidney injury through its cholesterol-lowering effect and also suppression of the pathways involved in oxidative stress, inflammation and NFκB activation.
Methods: Male rats were subjected to unilateral renal artery stenosis with silver-irritant coil, and then fed with 12-week hypercholesterolemic diet. Rats with renal artery stenosis were randomly assigned to two groups (n = 6 each) - ARD, or ARD+BBR - according to diet alone or in combination with BBR. Similarly, age-matched rats underwent sham operation and were also fed with hypercholesterolemic diet alone or in combination with BBR as two corresponding controls. Single-kidney hemodynamic metrics were measured in vivo with Doppler ultrasound to determine renal artery flow. The metrics reflecting hyperlipidemia, oxidative stress, renal structure and function, inflammation and NFκB activation were measured, respectively.
Results: Compared with control rats, ARD rats had a significant increase in urinary albumin, plasma cholesterol, LDL and thiobarbituric acid reactive substances (TBARS) and a significant decrease in SOD activity. When exposed to 12-week BBR, ARD rats had significantly lower levels in blood pressure, LDL, urinary albumin, and TBARS. In addition, there were significantly lower expression levels of iNOS and TGF-β in the ARD+BBR group than in the ARD group, with attenuated NFκB-DNA binding activity and down-regulated protein levels of subunits p65 and p50 as well as IKKβ.
Conclusions: We conclude that BBR can improve hypercholesterolemia and redox status in the kidney, eventually ameliorating chronic renal injury in rats with ARD, and that BBR can act against proinflammatory and profibrotic responses through suppression of the NFκB signaling pathway.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608549 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059794 | PLOS |
J Nephrol
October 2024
Department of Internal Medicine, Division of Nephrology, Marmara University, School of Medicine, Pendik Research and Education Hospital, Fevzi Cakmak Mah. Mimar Sinan Cd. N:41, Pendik, 34854, Istanbul, Turkey.
J Vasc Surg Cases Innov Tech
December 2024
Division of Vascular and Endovascular Surgery, Stony Brook University Hospital, Stony Brook, NY.
High Blood Press Cardiovasc Prev
September 2024
Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Turin, Via Genova 3, 10126, Turin, Italy.
Introduction: Renovascular hypertension (RVH) remains underdiagnosed despite its significant cardiovascular and renal morbidity.
Aim: This survey investigated screening and management practices for RVH among hypertensive patients in Italian hypertension centres in a real-life setting. Secondary, we analysed the current spread of renal denervation (RDN) and the criteria used for its eligibility.
Circ Cardiovasc Interv
September 2024
Renal Medicine, Salford Royal Hospital, United Kingdom (H.O.K., D.G., A.d.B., R.C., P.A.K.).
Background: The ASTRAL trial (Angioplasty and Stenting for Renal Artery Lesions) recruited 806 patients between 2000 and 2007. Patients with atherosclerotic renal artery stenosis (RAS) and clinician uncertainty about the benefit of revascularization were randomized 1:1 to medical therapy with or without renal artery stenting. The initial results were presented in 2009 at a median 33.
View Article and Find Full Text PDFJ Nephrol
July 2024
Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, M6 8HD, UK.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!